Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 2315Neoplasms 1678Prostatic Neoplasms 1178Lung Neoplasms 908Colorectal Neoplasms 873Carcinoma, Non-Small-Cell Lung 848Leukemia, Myeloid, Acute 587Pancreatic Neoplasms 568Multiple Myeloma 542Carcinoma, Hepatocellular 510Brain Neoplasms 509Neoplasm Metastasis 456Head and Neck Neoplasms 454Melanoma 410Ovarian Neoplasms 404Glioblastoma 397Precursor Cell Lymphoblastic Leukemia-Lymphoma 390Stomach Neoplasms 370Uterine Cervical Neoplasms 355Squamous Cell Carcinoma of Head and Neck 355Rectal Neoplasms 336Recurrence 332Hematologic Neoplasms 323Sarcoma 322Colonic Neoplasms 316Lymphoma 310Triple Negative Breast Neoplasms 284Urinary Bladder Neoplasms 279Glioma 277Carcinoma, Renal Cell 277

Interventions

pembrolizumab 1darolutamide 1bicalutamide 1abemaciclib 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Bulbo-Spinal Atrophy, X-Linked × 1 year × Clear all
NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

National Cancer Center Hospital East

Phase 2 Completed
57 enrolled
Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT06365788 2026-04-01

ABBICAR

Universitaire Ziekenhuizen KU Leuven

Phase 2 Recruiting
53 enrolled
Breast

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

NCT04090528 2025-12-05

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

University of Wisconsin, Madison

Phase 2 Active not recruiting
60 enrolled 10 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡